News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?
05 Sep 2023
Combination treatment with pembrolizumab and lenvatinib appears to be a better option for patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) with a platinum-free interval (PFI) of <6 months, suggests a recent study.
05 Sep 2023







